EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, RBC Bioscience's enterprise value is NT$628.5 Mil.
RBC Bioscience's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was NT$172.5 Mil. Therefore, RBC Bioscience's EV-to-Revenue for today is 3.64.
The historical rank and industry rank for RBC Bioscience's EV-to-Revenue or its related term are showing as below:
ROCO:6848'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.71 Med: 3.54 Max: 3.95
Current: 3.64
During the past 7 years, the highest EV-to-Revenue of RBC Bioscience was 3.95. The lowest was 0.71. And the median was 3.54.
ROCO:6848's EV-to-Revenue is ranked better than 69.1% of 1039
companies
in the Biotechnology industry
Industry Median: 8.18
vs ROCO:6848: 3.64
As of today (2024-05-26), RBC Bioscience's stock price is NT$15.95.
RBC Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was NT$13.26. Therefore, RBC Bioscience's PS Ratio for today is 1.20.
RBC Bioscience EV-to-Revenue Historical Data
The historical data trend for RBC Bioscience's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RBC Bioscience's EV-to-Revenue
For the Biotechnology subindustry, RBC Bioscience's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RBC Bioscience's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RBC Bioscience's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where RBC Bioscience's EV-to-Revenue falls into.
RBC Bioscience's current Enterprise Value is NT$628.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RBC Bioscience's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was NT$172.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RBC Bioscience's share price for today is NT$15.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was NT$13.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RBC Bioscience EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of RBC Bioscience's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
RBC Bioscience Corp is a bio sciences company. Its products include Real Genomics, MagCore Automated Nucleic Acid Extractor, and MagCore Nucleic Acid Extraction KIT.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6848 has been successfully added to your 